Alleviation of isoproterenol-induced myocardial fibrosis in mice by autophagy regulated by Astragaloside <b> Ⅳ</b> through activating ROCK/JNK pathway

WU Feifei; ZHANG Xiaoqi; LIAN Jing; YANG Jing; ZHAI Mengen; QIAO Rui; XU Chennian; YANG Tingting

doi:10.12206/j.issn.2097-2024.202212056

Volume 41 Issue 8

Aug. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2023 > 41(8): 478-484

WU Feifei, ZHANG Xiaoqi, LIAN Jing, YANG Jing, ZHAI Mengen, QIAO Rui, XU Chennian, YANG Tingting. Alleviation of isoproterenol-induced myocardial fibrosis in mice by autophagy regulated by Astragaloside Ⅳ through activating ROCK/JNK pathway[J]. Journal of Pharmaceutical Practice and Service, 2023, 41(8): 478-484. doi: 10.12206/j.issn.2097-2024.202212056

Citation:

WU Feifei, ZHANG Xiaoqi, LIAN Jing, YANG Jing, ZHAI Mengen, QIAO Rui, XU Chennian, YANG Tingting. Alleviation of isoproterenol-induced myocardial fibrosis in mice by autophagy regulated by Astragaloside Ⅳ through activating ROCK/JNK pathway[J]. Journal of Pharmaceutical Practice and Service, 2023, 41(8): 478-484. doi: 10.12206/j.issn.2097-2024.202212056

Alleviation of isoproterenol-induced myocardial fibrosis in mice by autophagy regulated by Astragaloside Ⅳ through activating ROCK/JNK pathway

doi: 10.12206/j.issn.2097-2024.202212056

1.
Department of Cardiovascular Surgery, the First Affiliated Hospital of Air Force Medical University, Xi’an 710032, China
2.
Department of the First Cadre Ward, General Hospital of Northern Theater Command, Shenyang 110016, China
3.
Department of Cardiothoracic Surgery, the Hospital of 79^th Group Army, Liaoyang 111000, China

Received Date: 2022-12-28
Rev Recd Date: 2023-06-04
Publish Date: 2023-08-25

Abstract

Objective To investigate the effect and mechanism of astragaloside Ⅳ(AS-Ⅳ) activating ROCK/JNK to regulate autophagy in improving isoproterenol (ISO) induced myocardial fibrosis (MF) in mice. Methods The mice were randomly divided into control operation group (Control group), ISO induced myocardial fibrosis group (MF group), AS-Ⅳ treatment group (AS-Ⅳ group) and combination group of astragaloside IV and Y-33075 (ROCK inhibitor) (astragaloside IV+Y-33075 group). After repeated administration for 30 days. The serum levels of LDH, BNP, CTGF in each group were detected. The cardiac function was detected by ultrasound. Myocardial structure and tissue fibrosis degree in each group were detected by Sirius Red and Masson staining. Oxidative stress (ROS) levels in myocardial tissue of each group were detected by DHE staining and the expression of ROCK, JNK, Atg5, Beclin 1, and LC3 Ⅰ/Ⅱ in myocardial tissue were detected by Western blotting. Results Compared with AS-Ⅳ group, the EF value of AS-Ⅳ+Y-33075 group decreased and the degree of myocardial fibrosis increased (P<0.05). The serum level of LDH, BNP, CTGF increased and the level of ROS in myocardial tissue increased while the expression of ROCK, JNK, Atg5, Beclin 1, LC3 Ⅰ/Ⅱ decreased (P<0.05). Y-33075 could block the protective effect of AS-Ⅳ on myocardial injury induced by MF and inhibit the regulation of AS-Ⅳ on ROCK and JNK. Conclusion AS-Ⅳ could attenuate myocardial fibrosis in mice by activating ROCK/JNK signal and promoting autophagy.
- myocardial fibrosis,
- autophagy,
- ROCK/JNK,
- astragaloside Ⅳ,
- mice

References

[1]	LIU J Y, LI W, DENG K Q, et al. The E3 ligase TRIM16 is a key suppressor of pathological cardiac hypertrophy[J]. Circ Res, 2022, 130(10): 1586-1600. doi: 10.1161/CIRCRESAHA.121.318866
[2]	YUAN J, LIU H B, GAO W, et al. MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress[J]. Theranostics, 2018, 8(9): 2565-2582. doi: 10.7150/thno.22878
[3]	DENG K Q, ZHAO G N, WANG Z H, et al. Targeting transmembrane BAX inhibitor motif containing 1 alleviates pathological cardiac hypertrophy[J]. Circulation, 2018, 137(14): 1486-1504. doi: 10.1161/CIRCULATIONAHA.117.031659
[4]	ZHAO G J, ZHAO C L, OUYANG S, et al. Ca²⁺-dependent NOX5 (NADPH oxidase 5) exaggerates cardiac hypertrophy through reactive oxygen species production[J]. Hypertension, 2020, 76(3): 827-838. doi: 10.1161/HYPERTENSIONAHA.120.15558
[5]	ZHOU H, LI Y J, WANG M, et al. Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes[J]. Acta Pharmacol Sin, 2011, 32(8): 999-1008. doi: 10.1038/aps.2011.54
[6]	KANLAYA R, THONGBOONKERD V. Persistent Escherichia coli infection in renal tubular cells enhances calcium oxalate crystal-cell adhesion by inducing ezrin translocation to apical membranes via Rho/ROCK pathway[J]. Cell Mol Life Sci, 2022, 79(7): 381. doi: 10.1007/s00018-022-04414-y
[7]	FENG H, ZHU X Y, TANG Y, et al. Astragaloside Ⅳ ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome-mediated inflammation[J]. Int J Mol Med, 2021, 48(2): 164. doi: 10.3892/ijmm.2021.4996
[8]	底雪梅, 袁曜晖, 张超, 等. 黄芪甲苷抑制U937巨噬细胞CCL18表达及其作用机制研究[J]. 药学实践杂志, 2019, 37(1): 32-36, 41.
[9]	ZHANG X, QU H, YANG T, et al. Astragaloside Ⅳ attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway[J]. Cell Cycle, 2022, 21(21): 2309-2322. doi: 10.1080/15384101.2022.2093598
[10]	CHEN Y M, GE Z W, HUANG S X, et al. Delphinidin attenuates pathological cardiac hypertrophy via the AMPK/NOX/MAPK signaling pathway[J]. Aging, 2020, 12(6): 5362-5383. doi: 10.18632/aging.102956
[11]	LIU W J, WANG G, ZHANG C C, et al. MG53, A novel regulator of KChIP2 and Ito, f, plays a critical role in electrophysiological remodeling in cardiac hypertrophy[J]. Circulation, 2019, 139: 2142-2156. doi: 10.1161/CIRCULATIONAHA.118.029413
[12]	LIN H B, NAITO K, OH Y, et al. Innate immune Nod1/RIP2 signaling is essential for cardiac hypertrophy but requires mitochondrial antiviral signaling protein for signal transductions and energy balance[J]. Circulation, 2020, 142(23): 2240-2258. doi: 10.1161/CIRCULATIONAHA.119.041213
[13]	LI P L, LIU H, CHEN G P, et al. STEAP3 (Si_x-transmembrane epithelial antigen of prostate 3) inhibits pathological cardiac hypertrophy[J]. Hypertension, 2020, 76(4): 1219-1230. doi: 10.1161/HYPERTENSIONAHA.120.14752
[14]	WU X Q, LIU Z M, YU X Y, et al. Autophagy and cardiac diseases: therapeutic potential of natural products[J]. Med Res Rev, 2021, 41(1): 314-341. doi: 10.1002/med.21733
[15]	VANHOUTTE D, SCHIPS T G, VO A, et al. Thbs1 induces lethal cardiac atrophy through PERK-ATF4 regulated autophagy[J]. Nat Commun, 2021, 12(1): 3928. doi: 10.1038/s41467-021-24215-4
[16]	TONG M M, SAITO T, ZHAI P Y, et al. Alternative mitophagy protects the heart against obesity-associated cardiomyopathy[J]. Circ Res, 2021, 129(12): 1105-1121. doi: 10.1161/CIRCRESAHA.121.319377
[17]	DENG Z H, JIA Y M, LIU H F, et al. RhoA/ROCK pathway: implication in osteoarthritis and therapeutic targets[J]. Am J Transl Res, 2019, 11(9): 5324-5331.
[18]	WANG Z H, REN D B, ZHENG P. The role of Rho/ROCK in epileptic seizure-related neuronal damage[J]. Metab Brain Dis, 2022, 37(4): 881-887. doi: 10.1007/s11011-022-00909-6
[19]	DIETERLE M P, HUSARI A, STEINBERG T, et al. Role of mechanotransduction in periodontal homeostasis and disease[J]. J Dent Res, 2021, 100(11): 1210-1219. doi: 10.1177/00220345211007855
[20]	GUO M, XU J M, WANG S W, et al. Asiaticoside reduces autophagy and improves memory in a rat model of dementia through mTOR signaling pathway regulation[J]. Mol Med Rep, 2021, 24(3): 645. doi: 10.3892/mmr.2021.12284
[21]	LI Y C, WANG H H, ZHANG R, et al. Antitumor activity of asiaticoside against multiple myeloma drug-resistant cancer cells is mediated by autophagy induction, activation of effector caspases, and inhibition of cell migration, invasion, and STAT-3 signaling pathway[J]. Med Sci Monit, 2019, 25: 1355-1361. doi: 10.12659/MSM.913397

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views(1658) PDF downloads(12) Cited by()

Proportional views

HTML

病理性心肌纤维化(myocardial fibrosis, MF)是常见的心血管病理生理表现，存在于多种心血管疾病，具体机制尚不明确，减轻心肌纤维化可能成为缓解房颤等多种心血管疾病治疗的有效靶点^[1-4]，但目前心肌纤维化的治疗尚缺乏有效治疗策略。研究表明，Rho/ROCK/JNK途径调节多种关键细胞功能，可以介导细胞凋亡、增殖、分化等，而抑制JNK和TGFβ/Smad途径可改善2型糖尿病大鼠的心肌纤维化，使RhoA/ROCK/JNK成为预防心肌纤维化的潜在治疗靶点^{[5- 6]}。黄芪甲苷（astragaloside Ⅳ, AS-Ⅳ）是从中药黄芪中提取出的主要活性成分，具有抗氧化、抗炎症、降低血糖等多重药理作用, 并且AS-Ⅳ通过抑制ROS/Caspase-1/GSDMD信号通路可减轻心肌梗死诱导的心肌纤维化和心脏重塑^[7-9]。本研究采用异丙肾上腺素诱导小鼠心肌纤维化，探讨黄芪甲苷对心肌纤维化的改善作用以及对ROCK/JNK信号的调控作用。

1. 材料

6周龄健康雄性C57/BL小鼠，体质量（20.5±1.1） g，购自空军军医大学实验动物中心[许可证号：SYXK（陕）2019-001]，实验经空军军医大学伦理委员会批准（No.20220262）；Atg5、Beclin-1、LC3 Ⅰ/Ⅱ、ROCK、JNK、GAPDH抗体、黄芪甲苷（美国Sigma-Aldrich公司）；ROCK抑制剂Y-33075（上海阿拉丁生化科技股份有限公司）；异丙肾上腺素（ISO，天津泰泽兴业生物科技有限公司）；BNP试剂盒、结缔组织生长因子（CTGF）试剂盒（美国R＆D Systems公司）；超氧化物阴离子荧光检测探针（DHE，美国ThermoFisher公司）；多功能酶标仪（美国Thermo公司）；Olympus FV2000激光共聚焦显微镜（日本奥林巴斯公司）；小动物超声仪（美国VisualSonics公司）。

2. 方法

2.1. 分组及心肌纤维化模型建立

将60只C57/BL小鼠按照随机数字表法随机分成4组，每组15只，即对照组、心肌纤维化组（MF组）、黄芪甲苷组、黄芪甲苷联合ROCK抑制剂Y-33075组（黄芪甲苷+Y-33075组）。各组以普通饲料喂养，MF组、黄芪甲苷组、黄芪甲苷+Y-33075组于小鼠肩胛间皮下注射异丙肾上腺素（ISO），首次剂量为 5 mg/(kg·d)，后以2.5 mg/(kg·d)，重复给药持续30 d，诱导心肌纤维化模型。对照组于同一部位注射相同体积生理盐水。给药组在造模同时给与药物治疗，黄芪甲苷组按100 mg/(kg·d）腹腔注射黄芪甲苷，黄芪甲苷+Y-33075组分别按100 mg/(kg·d）和10 mg/(kg·d)腹腔注射黄芪甲苷和Y-33075，MF组和对照组腹腔注射等量生理盐水，重复给药持续30 d。

2.2. 心脏超声检测各组小鼠心功能

各组小鼠经2%异氟烷麻醉后，四肢插上超声仪电极，探头在乳头肌水平位置用M型取样线检测，测量并计算得出左心室射血分数（LVEF）、左心室短轴缩短率（LVFS）、左心室舒张期前壁厚度（LVAWd）、左心室舒张末期容积（LVEDV）等指标。

2.3. 酶联免疫吸附实验（ELISA）检测小鼠血清LDH、BNP、CTGF水平

固定小鼠，剪开并剥离小鼠颈部皮肤、皮下组织，暴露小鼠颈动脉，剪开快速取血2 ml至EP管中，3000 r/min离心15 min，取上层清亮血清。按照LDH、BNP、CTGF检测试剂盒说明书检测。

2.4. Masson、天狼星红、DHE染色检测各组小鼠心肌纤维化程度及ROS水平

迅速剪下心脏，冷PBS缓冲液冲洗3遍，洗净血细胞后，以多聚甲醛（40 g/L）固定72 h，石蜡包埋、切片，行Masson、天狼星红染色，在光学显微镜下拍摄染色后的Masson、天狼星红图像并保存，使用Image J软件测定Masson染色中胶原阳性蓝色染色面积与组织总面积比值，即胶原容积分数。

心脏在液氮中快速冷冻，并切成3 μm厚的切片。冷冻组织切片在黑暗潮湿的小室中用DHE反应混合物染色。使用Olympus FV1000激光共聚焦显微镜检查每个样品。使用Image J软件测定切片中二氢乙锭的荧光强度，以评估心肌组织中活性氧簇（ROS）的产生。

2.5. qPCR检测各组小鼠心肌组织BNP、CTGF、Atg5的mRNA相对表达量

测定BNP、CTGF、Atg5的表达评估心肌组织纤维化及自噬水平。用TRIzol试剂从组织中分离总RNA，逆转录实验生成cDNA，用BIO-RAD分光光度法测定RNA和cDNA的浓度和纯度，PrimerPremier 6.0软件设计引物并合成（上海吉凯基因有限公司）。在iQ™5 RT-PCR系统中进行PCR扩增，采用2^−ΔΔct法对靶基因表达量进行相对定量。各检测基因引物序列由美国复能基因公司提供（见表1）。

基因	上游序列(5'-3')	下游序列(5'-3')
BNP	TAGCCAGTCTCCAGAACAAATCC	AAACAACCTCAGCCCGTCA
CTGF	CAGCATGGACGTTCGTCTG	AACCACGGTTTGGTCCTTGG
Atg5	CAGAAGCTGTTCCGTCCTGT	CCGTGAATCATCACCTGGCT
GAPDH	AGAACATCATCCCTGCATCC	AGTTGCTGTTGAAGTCGC

2.6. 蛋白印迹法检测心肌纤维化组织中自噬的变化

各组小鼠心肌组织取相同质量放入离心管中，加入预冷PBS，剪碎心肌组织，4℃ 3000 r/min离心10 min，弃上清，沉淀中加入含蛋白酶抑制剂的RIPA强裂解液，冰上充分研磨并裂解30 min，4℃ 12000 r/min离心30 min，取上清；BCA法蛋白定量；电泳并用湿转法将蛋白转移至PVDF膜，5%脱脂奶粉室温下封闭2 h，裁剪目的条带，放入对应ROCK（1∶1000）、JNK（1∶1000）、Beclin 1（1∶1000）、LC3 Ⅰ/Ⅱ（1∶1000）、Atg5（1∶1000）和GAPDH抗体（1∶5000）中，4℃摇床孵育过夜；TBST洗脱3次，5 min/次，将目的条带放入山羊抗兔或抗鼠二抗（1∶5000）中室温摇床孵育2 h，TBST洗脱3次，5 min/次，ECL化学发光液避光检测，Image Lab统计灰度值。

2.7. LC3 Ⅰ/Ⅱ免疫荧光染色检测心肌组织自噬程度

取小鼠左室前壁组织，石蜡包埋、切片、脱蜡、复水，用PBS缓冲溶液洗5次，每次3 min，Triton-X100（2 g/L）处理15 min，PBS液冲洗3次，每次3 min，山羊血清室温封闭1.5 h，PBS液洗3次，每次3 min，每个切片加LC3 Ⅰ/Ⅱ抗体（1∶100）50 μl，4 ℃孵育15 h，PBS液洗5次，每次3 min，暗室内每张切片加荧光二抗（1∶500） 50 μl，PBS液洗5次（3 min/次），避光条件下每张切片加DAPI溶液50 μl，PBS液洗5次，每次3 min，用荧光防淬灭液封片，采集图像。

2.8. 统计学分析

数据采用GraphPad Prism 9.0软件统计和分析。计量资料以（均数±标准差）表示，多组间比较采用单因素方差分析，随后采用Bonferroni校正及post hoc t检验，P<0.05为差异具有统计学意义。

4. 讨论

病理性心肌纤维化是由多种因素引起的，这些因素可导致胶原纤维过度沉积，胶原浓度和体积分数显著增强，心肌胶原类型和结构排列紊乱，是房颤等多种慢性心血管疾病进展中的重要病理过程，然而心肌纤维化在分子水平的具体机制尚不清楚^[10-13]。研究表明，多种重要机制参与了病理性心肌纤维化的发展过程，其中包括炎症反应、氧化应激、纤维化、细胞死亡等。近年来发现，自噬和泛素-蛋白酶体系统是维持细胞中蛋白稳态的重要途径，研究表明自噬在心肌纤维化过程中起着重要作用^[14-16]。然而，自噬与心肌纤维化的相互作用机制尚不十分清楚，自噬及其调节可能成为治疗心肌纤维化的潜在策略。

近年来多项研究发现，一种来源于豆科植物蒙古黄芪或膜荚黄芪的黄酮类化合物黄芪甲苷，在心血管相关疾病中发挥了重要的保护作用^[13-14]。然而，黄芪甲苷能否减轻心肌纤维化及其潜在分子机制还有待进一步探究。

本研究旨在探讨自噬与小鼠心肌纤维化的关系，并阐明了黄芪甲苷通过上调自噬改善MF的保护机制。根据本研究结果发现，心肌细胞自噬抑制参与了MF进展，同时，黄芪甲苷可激活ROCK/JNK通路促进细胞自噬改善MF，结果从一定从程度上阐明了MF的可能作用机制，并辅助探寻预防和治疗心肌纤维化的潜在靶点。

Rho蛋白激酶(ROCK)是丝氨酸蛋白激酶家族成员， Rho/ROCK途径调节多种关键细胞功能，如基因转录、细胞黏附、神经发育、细胞死亡^[5-6]。Rho/ROCK的相关研究有助于更好地阐明多种疾病的病理生理过程，而抑制Rho/ROCK也可能成为潜在治疗靶点^[17-19]。细胞自噬在心肌纤维化中起着关键作用，ROCK/.JNK具有自噬调控作用^[17]。黄芪甲苷的心脏保护作用是通过激活细胞自噬介导^[20-21]。本实验结果表明，在MF模型中，ROCK和JNK表达均下调，而黄芪甲苷组ROCK和JNK表达恢复。Y-33075是ROCK的抑制剂，Y-33075处理后可通过阻断ROCK减弱黄芪甲苷对MF的改善作用。因此，通过抑制ROCK/JNK通路，部分消除了黄芪甲苷对MF的改善作用以及黄芪甲苷调控细胞自噬的影响。

综上，本研究的结果表明黄芪甲苷通过激活ROCK/JNK通路促进自噬发挥保护作用，并发现MF与ROCK/JNK通路介导的自噬有关。然而，自噬在MF等不同疾病的特定阶段的具体作用机制仍不十分明确，自噬、MF以及两者之间的关系需要深入研究与进一步探索。

Reference (21)

[1]	LIU J Y, LI W, DENG K Q, et al. The E3 ligase TRIM16 is a key suppressor of pathological cardiac hypertrophy[J]. Circ Res, 2022, 130(10): 1586-1600.
[2]	YUAN J, LIU H B, GAO W, et al. MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress[J]. Theranostics, 2018, 8(9): 2565-2582.
[3]	DENG K Q, ZHAO G N, WANG Z H, et al. Targeting transmembrane BAX inhibitor motif containing 1 alleviates pathological cardiac hypertrophy[J]. Circulation, 2018, 137(14): 1486-1504.
[4]	ZHAO G J, ZHAO C L, OUYANG S, et al. Ca²⁺-dependent NOX5 (NADPH oxidase 5) exaggerates cardiac hypertrophy through reactive oxygen species production[J]. Hypertension, 2020, 76(3): 827-838.
[5]	ZHOU H, LI Y J, WANG M, et al. Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes[J]. Acta Pharmacol Sin, 2011, 32(8): 999-1008.
[6]	KANLAYA R, THONGBOONKERD V. Persistent Escherichia coli infection in renal tubular cells enhances calcium oxalate crystal-cell adhesion by inducing ezrin translocation to apical membranes via Rho/ROCK pathway[J]. Cell Mol Life Sci, 2022, 79(7): 381.
[7]	FENG H, ZHU X Y, TANG Y, et al. Astragaloside Ⅳ ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome-mediated inflammation[J]. Int J Mol Med, 2021, 48(2): 164.
[8]	底雪梅, 袁曜晖, 张超, 等. 黄芪甲苷抑制U937巨噬细胞CCL18表达及其作用机制研究[J]. 药学实践杂志, 2019, 37(1): 32-36, 41.
[9]	ZHANG X, QU H, YANG T, et al. Astragaloside Ⅳ attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway[J]. Cell Cycle, 2022, 21(21): 2309-2322.
[10]	CHEN Y M, GE Z W, HUANG S X, et al. Delphinidin attenuates pathological cardiac hypertrophy via the AMPK/NOX/MAPK signaling pathway[J]. Aging, 2020, 12(6): 5362-5383.
[11]	LIU W J, WANG G, ZHANG C C, et al. MG53, A novel regulator of KChIP2 and Ito, f, plays a critical role in electrophysiological remodeling in cardiac hypertrophy[J]. Circulation, 2019, 139: 2142-2156.
[12]	LIN H B, NAITO K, OH Y, et al. Innate immune Nod1/RIP2 signaling is essential for cardiac hypertrophy but requires mitochondrial antiviral signaling protein for signal transductions and energy balance[J]. Circulation, 2020, 142(23): 2240-2258.
[13]	LI P L, LIU H, CHEN G P, et al. STEAP3 (Si_x-transmembrane epithelial antigen of prostate 3) inhibits pathological cardiac hypertrophy[J]. Hypertension, 2020, 76(4): 1219-1230.
[14]	WU X Q, LIU Z M, YU X Y, et al. Autophagy and cardiac diseases: therapeutic potential of natural products[J]. Med Res Rev, 2021, 41(1): 314-341.
[15]	VANHOUTTE D, SCHIPS T G, VO A, et al. Thbs1 induces lethal cardiac atrophy through PERK-ATF4 regulated autophagy[J]. Nat Commun, 2021, 12(1): 3928.
[16]	TONG M M, SAITO T, ZHAI P Y, et al. Alternative mitophagy protects the heart against obesity-associated cardiomyopathy[J]. Circ Res, 2021, 129(12): 1105-1121.
[17]	DENG Z H, JIA Y M, LIU H F, et al. RhoA/ROCK pathway: implication in osteoarthritis and therapeutic targets[J]. Am J Transl Res, 2019, 11(9): 5324-5331.
[18]	WANG Z H, REN D B, ZHENG P. The role of Rho/ROCK in epileptic seizure-related neuronal damage[J]. Metab Brain Dis, 2022, 37(4): 881-887.
[19]	DIETERLE M P, HUSARI A, STEINBERG T, et al. Role of mechanotransduction in periodontal homeostasis and disease[J]. J Dent Res, 2021, 100(11): 1210-1219.
[20]	GUO M, XU J M, WANG S W, et al. Asiaticoside reduces autophagy and improves memory in a rat model of dementia through mTOR signaling pathway regulation[J]. Mol Med Rep, 2021, 24(3): 645.
[21]	LI Y C, WANG H H, ZHANG R, et al. Antitumor activity of asiaticoside against multiple myeloma drug-resistant cancer cells is mediated by autophagy induction, activation of effector caspases, and inhibition of cell migration, invasion, and STAT-3 signaling pathway[J]. Med Sci Monit, 2019, 25: 1355-1361.

Name
E-mail
Phone
Title
Content
Verification Code

检测项目	对照组	MF组	黄芪甲苷组	黄芪甲苷+ Y-33075组
LVEF (%)	72.31±6.27	35.43±8.12^*	55.25±7.43^{^}	40.28±11.36^#
LVAWd (mm)	1.51±0.03	1.94±0.25^*	1.62±0.20^{^}	1.71±0.18^#
LVEDV(μl)	57.92±7.23	49.78±9.36^*	56.32±6.28^	50.79±5.46^#
^*P<0.05，与对照组比较；^{^}P<0.05，与MF组比较；^#P<0.05，与黄芪甲苷组比较

检测项目	对照组	MF组	黄芪甲苷组	黄芪甲苷+Y-33075组
LDH（U/L）	395.25±30.38	1102.43±62.35^*	500.89±19.48^{^}	974.21±101.72^#
BNP（ng/L）	80.29±12.90	200.61±31.92^*	137.33±19.28^{^}	194.72±26.31^#
CTGF（ng/L）	121.91±20.25	213.37±29.58^*	163.05±10.29^{^}	189.03±25.42^#
^*P<0.05，与对照组比较；^{^}P<0.05，与MF组比较；^#P<0.05，与黄芪甲苷组比较

项目	对照组	MF组	黄芪甲苷组	黄芪甲苷+Y-33075组
BNP	1	4.02±0.59^*	1.59±0.33^{^}	3.98±0.49^#
CTGF	1	1.62±0.23^*	0.91±0.37^{^}	1.54±0.29^#
Atg5	1	0.53±0.09^*	2.56±0.61^{^}	0.69±0.30^#
^*P<0.05，与对照组比较；^{^}P<0.05，与MF组比较；^#P<0.05，与黄芪甲苷组比较

Message Board